These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 35860905)
1. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling. Brown NE; Jones A; Hunt BG; Waltz SE Prostate; 2022 Nov; 82(15):1422-1437. PubMed ID: 35860905 [TBL] [Abstract][Full Text] [Related]
2. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation. Brown NE; Paluch AM; Nashu MA; Komurov K; Waltz SE Neoplasia; 2018 Sep; 20(9):917-929. PubMed ID: 30121008 [TBL] [Abstract][Full Text] [Related]
3. Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Al-Janabi H; Moyes K; Allen R; Fisher M; Crespo M; Gurel B; Rescigno P; de Bono J; Nunns H; Bailey C; Junker-Jensen A; Muthana M; Phillips WA; Pearson HB; Taplin ME; Brown JE; Lewis CE J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060021 [TBL] [Abstract][Full Text] [Related]
4. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Chen S; Cai C; Sowalsky AG; Ye H; Ma F; Yuan X; Simon NI; Gray NS; Balk SP Cancer Res; 2018 Sep; 78(18):5203-5215. PubMed ID: 30012673 [TBL] [Abstract][Full Text] [Related]
6. Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer. Batth I; Yun H; Hussain S; Meng P; Osmulski P; Huang TH; Bedolla R; Profit A; Reddick R; Kumar A Oncotarget; 2016 Mar; 7(12):14048-63. PubMed ID: 26872377 [TBL] [Abstract][Full Text] [Related]
7. Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer. Batth IS; Yun H; Kumar AP Mol Carcinog; 2015 Oct; 54(10):937-46. PubMed ID: 26152593 [TBL] [Abstract][Full Text] [Related]
8. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. El-Kenawi A; Dominguez-Viqueira W; Liu M; Awasthi S; Abraham-Miranda J; Keske A; Steiner KK; Noel L; Serna AN; Dhillon J; Gillies RJ; Yu X; Koomen JM; Yamoah K; Gatenby RA; Ruffell B Cancer Res; 2021 Nov; 81(21):5477-5490. PubMed ID: 34301759 [TBL] [Abstract][Full Text] [Related]
9. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor. Patki M; Huang Y; Ratnam M Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779 [TBL] [Abstract][Full Text] [Related]
10. Prostate Epithelial RON Signaling Promotes M2 Macrophage Activation to Drive Prostate Tumor Growth and Progression. Sullivan C; Brown NE; Vasiliauskas J; Pathrose P; Starnes SL; Waltz SE Mol Cancer Res; 2020 Aug; 18(8):1244-1254. PubMed ID: 32439702 [TBL] [Abstract][Full Text] [Related]
11. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer. O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095 [TBL] [Abstract][Full Text] [Related]
12. Targeting the androgen receptor signaling pathway in advanced prostate cancer. Chung C; Abboud K Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118 [TBL] [Abstract][Full Text] [Related]
13. Effect of dietary omega-3 fatty acids on castrate-resistant prostate cancer and tumor-associated macrophages. Liang P; Henning SM; Guan J; Grogan T; Elashoff D; Cohen P; Aronson WJ Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):127-135. PubMed ID: 31439889 [TBL] [Abstract][Full Text] [Related]